Valuing And Pricing Remdesivir: Should Drug Makers Get Paid For Helping Us Get Back To Work?

Watch out! New leading-edge analysis available on Valuing Remdesivir

The Institute for Clinical and Economic Review (ICER), the private, nonprofit organization that has become a kind of national arbiter for appropriate pricing for pharmaceuticals in the United States, has weighed in, presenting on May 1 two approaches for pricing remdesivir. 

A real added value from the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center

read the full analysis on the Health Affairs website: Click here


For adding comments please sign up or log in
Thanks so much Dan, this is extremely useful and and an excellent piece of work as usual!